NCT03610490View on ClinicalTrials.gov

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

August 21, 2024

Study Completion Date

August 21, 2024

Conditions
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Ovarian CarcinosarcomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes MDA-TIL

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Interleukin-2

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Iovance Biotherapeutics

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER